Literature DB >> 21143420

Involvement of sphingosine-1-phosphate/RhoA/Rho-kinase signaling pathway in corporal fibrosis following cavernous nerve injury in male rats.

Min Chul Cho1, Kwanjin Park, Ji Sun Chai, Sun Hee Lee, Soo Woong Kim, Jae-Seung Paick.   

Abstract

INTRODUCTION: Postprostatectomy erectile dysfunction (ED) is thought to be due primarily to injury to cavernous nerve (CN) during surgery. The molecular mechanisms leading to ED after CN injury are poorly understood. AIM: We determined whether transforming growth factor-β(1) (TGF-β(1)), sphingosine-1-phosphate (S1P) and RhoA/Rho-kinase (ROCK) signaling pathways were involved in corporal fibrosis after bilateral CN injury in rats.
METHODS: Forty-eight 10-week-old male Sprague-Dawley rats were equally divided into the following four groups: normal control group (C); sham surgery group (S); bilateral CN crush injury group (I); and bilateral CN transection group (T). Within each of the four groups, two subgroups were analyzed as a function of time (1 and 8 weeks postoperatively). MAIN OUTCOME MEASURES: Penile tissue was processed for immunoblot (RhoA, ROCK1, phospho-myosin phosphatase target subunit [MYPT1]), reverse transcription-polymerase chain reaction (RT-PCR) (TGF-β(1), sphingosine kinase type 1 [SphK1], and S1P(2)), immunohistochemistry (alpha smooth muscle actin [α-SMA]), and Masson's trichrome staining.
RESULTS: At 1 and 8 weeks postoperatively, the I and T groups had a significantly decreased smooth muscle cell/collagen ratio, the expression of α-SMA and phospho-MYPT1 compared to the C group. Densitometry revealed a significantly higher expression of RhoA and ROCK1 in the T group compared to the C group at 1 and 8 weeks postoperatively. For the I group, the expression of RhoA significantly increased starting from 1 week postoperatively, but the expression of ROCK1 significantly increased as late as 8 weeks following injury. The expression of TGF-β(1) and S1P(2) mRNA in the I or T group remained significantly increased up to 8 weeks compared to the C group, despite significant reduction at 8 weeks compared to 1 week postoperatively. The expression of SphK1 mRNA in the I and T groups was significantly increased at 1 week but not 8 weeks postoperatively.
CONCLUSIONS: Our data suggest that S1P and RhoA/ROCK1 signaling may be involved in corporal fibrosis associated with loss of smooth muscle through coordination with TGF-β(1) after CN injury.
© 2010 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21143420     DOI: 10.1111/j.1743-6109.2010.02147.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  18 in total

1.  Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury.

Authors:  Johanna L Hannan; Maarten Albersen; Omer Kutlu; Christian Gratzke; Christian G Stief; Arthur L Burnett; Jeffrey J Lysiak; Petter Hedlund; Trinity J Bivalacqua
Journal:  J Urol       Date:  2012-09-25       Impact factor: 7.450

2.  cAMP-dependent post-translational modification of neuronal nitric oxide synthase neuroprotects penile erection in rats.

Authors:  Serkan Karakus; Biljana Musicki; Justin D La Favor; Arthur L Burnett
Journal:  BJU Int       Date:  2017-08-22       Impact factor: 5.588

3.  Recombinant PAI-1 therapy restores myoendothelial junctions and erectile function in PAI-1-deficient mice.

Authors:  P K Kavoussi; K Heberlein; A C Straub; G J Lowe; J L Oliver; R P Smith; W D Steers; B H Annex; B E Isakson; J J Lysiak
Journal:  Andrologia       Date:  2014-12-29       Impact factor: 2.775

4.  Essential Roles of RNA-binding Protein HuR in Activation of Hepatic Stellate Cells Induced by Transforming Growth Factor-β1.

Authors:  Jingjing Ge; Na Chang; Zhongxin Zhao; Lei Tian; Xianghui Duan; Lin Yang; Liying Li
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

5.  ZYZ-168 alleviates cardiac fibrosis after myocardial infarction through inhibition of ERK1/2-dependent ROCK1 activation.

Authors:  Shanshan Luo; Tran Ba Hieu; Fenfen Ma; Ying Yu; Zhonglian Cao; Minjun Wang; Weijun Wu; Yicheng Mao; Peter Rose; Betty Yuen-Kwan Law; Yi Zhun Zhu
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

Review 6.  Revisiting the Regenerative Therapeutic Advances Towards Erectile Dysfunction.

Authors:  Ming-Che Liu; Meng-Lin Chang; Ya-Chun Wang; Wei-Hung Chen; Chien-Chih Wu; Shauh-Der Yeh
Journal:  Cells       Date:  2020-05-19       Impact factor: 6.600

7.  Role of inhibiting LIM-kinase2 in improving erectile function through suppression of corporal fibrosis in a rat model of cavernous nerve injury.

Authors:  Juhyun Park; Sung Yong Cho; Kwanjin Park; Ji Sun Chai; Hwancheol Son; Soo Woong Kim; Jae-Seung Paick; Min Chul Cho
Journal:  Asian J Androl       Date:  2018 Jul-Aug       Impact factor: 3.285

8.  Chronic treatment with Ang-(1-7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes.

Authors:  Mariam H M Yousif; Batoul Makki; Ahmed Z El-Hashim; Saghir Akhtar; Ibrahim F Benter
Journal:  J Diabetes Res       Date:  2014-09-16       Impact factor: 4.011

9.  Caspase-3 dependent nitrergic neuronal apoptosis following cavernous nerve injury is mediated via RhoA and ROCK activation in major pelvic ganglion.

Authors:  Johanna L Hannan; Hotaka Matsui; Nikolai A Sopko; Xiaopu Liu; Emmanuel Weyne; Maarten Albersen; Joseph W Watson; Ahmet Hoke; Arthur L Burnett; Trinity J Bivalacqua
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

10.  Reduced corporal fibrosis to protect erectile function by inhibiting the Rho-kinase/LIM-kinase/cofilin pathway in the aged transgenic rat harboring human tissue kallikrein 1.

Authors:  Kai Cui; Yang Luan; Tao Wang; Li Zhuan; Ke Rao; Shao-Gang Wang; Zhang-Qun Ye; Ji-Hong Liu; Dao-Wen Wang
Journal:  Asian J Androl       Date:  2017 Jan-Feb       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.